Tags

Type your tag names separated by a space and hit enter

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention.
J Headache Pain. 2019 Jan 16; 20(1):6.JH

Abstract

BACKGROUND AND AIM

Monoclonal antibodies acting on the calcitonin gene-related peptide or on its receptor are new drugs to prevent migraine. Four monoclonal antibodies have been developed: one targeting the calcitonin gene-related peptide receptor (erenumab) and three targeting the calcitonin gene-related peptide (eptinezumab, fremanezumab, and galcanezumab). The aim of this document by the European Headache Federation (EHF) is to provide an evidence-based and expert-based guideline on the use of the monoclonal antibodies acting on the calcitonin gene-related peptide for migraine prevention.

METHODS

The guideline was developed following the Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) approach. The working group identified relevant questions, performed systematic review and analysis of the literature, assessed the quality of available evidence, and wrote recommendations. Where the GRADE approach was not applicable, expert opinion was provided.

RESULTS

We found low to high quality of evidence to recommend eptinezumab, erenumab, fremanezumab, and galcanezumab in patients with episodic migraine and medium to high quality of evidence to recommend erenumab, fremanezumab, and galcanezumab in patients with chronic migraine. For several clinical questions, there was not enough evidence to provide recommendations using the GRADE approach and recommendations relied on experts' opinion.

CONCLUSION

Monoclonal antibodies acting on the calcitonin gene-related peptide are new drugs which can be recommended for migraine prevention. Real life data will be useful to improve the use of those drugs in clinical practice.

Authors+Show Affiliations

Neuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, via Vetoio, 67100, L'Aquila, Italy. simona.sacco@univaq.it.Department of Neurology, Danish Headache Center, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.Department of Neurology, Danish Headache Center, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany.Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.1st Department of Neurology, National and Kapodistrian University of Athens, Athens, Greece.Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.

Pub Type(s)

Journal Article
Practice Guideline
Systematic Review

Language

eng

PubMed ID

30651064

Citation

Sacco, Simona, et al. "European Headache Federation Guideline On the Use of Monoclonal Antibodies Acting On the Calcitonin Gene Related Peptide or Its Receptor for Migraine Prevention." The Journal of Headache and Pain, vol. 20, no. 1, 2019, p. 6.
Sacco S, Bendtsen L, Ashina M, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20(1):6.
Sacco, S., Bendtsen, L., Ashina, M., Reuter, U., Terwindt, G., Mitsikostas, D. D., & Martelletti, P. (2019). European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. The Journal of Headache and Pain, 20(1), 6. https://doi.org/10.1186/s10194-018-0955-y
Sacco S, et al. European Headache Federation Guideline On the Use of Monoclonal Antibodies Acting On the Calcitonin Gene Related Peptide or Its Receptor for Migraine Prevention. J Headache Pain. 2019 Jan 16;20(1):6. PubMed PMID: 30651064.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. AU - Sacco,Simona, AU - Bendtsen,Lars, AU - Ashina,Messoud, AU - Reuter,Uwe, AU - Terwindt,Gisela, AU - Mitsikostas,Dimos-Dimitrios, AU - Martelletti,Paolo, Y1 - 2019/01/16/ PY - 2018/12/13/received PY - 2018/12/27/accepted PY - 2019/1/18/entrez PY - 2019/1/18/pubmed PY - 2019/3/15/medline KW - Calcitonin gene-related peptide KW - Chronic migraine KW - Eptinezumab KW - Erenumab KW - Fremanezumab KW - Galcazenumab KW - Migraine KW - Prevention SP - 6 EP - 6 JF - The journal of headache and pain JO - J Headache Pain VL - 20 IS - 1 N2 - BACKGROUND AND AIM: Monoclonal antibodies acting on the calcitonin gene-related peptide or on its receptor are new drugs to prevent migraine. Four monoclonal antibodies have been developed: one targeting the calcitonin gene-related peptide receptor (erenumab) and three targeting the calcitonin gene-related peptide (eptinezumab, fremanezumab, and galcanezumab). The aim of this document by the European Headache Federation (EHF) is to provide an evidence-based and expert-based guideline on the use of the monoclonal antibodies acting on the calcitonin gene-related peptide for migraine prevention. METHODS: The guideline was developed following the Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) approach. The working group identified relevant questions, performed systematic review and analysis of the literature, assessed the quality of available evidence, and wrote recommendations. Where the GRADE approach was not applicable, expert opinion was provided. RESULTS: We found low to high quality of evidence to recommend eptinezumab, erenumab, fremanezumab, and galcanezumab in patients with episodic migraine and medium to high quality of evidence to recommend erenumab, fremanezumab, and galcanezumab in patients with chronic migraine. For several clinical questions, there was not enough evidence to provide recommendations using the GRADE approach and recommendations relied on experts' opinion. CONCLUSION: Monoclonal antibodies acting on the calcitonin gene-related peptide are new drugs which can be recommended for migraine prevention. Real life data will be useful to improve the use of those drugs in clinical practice. SN - 1129-2377 UR - https://www.unboundmedicine.com/medline/citation/30651064/European_headache_federation_guideline_on_the_use_of_monoclonal_antibodies_acting_on_the_calcitonin_gene_related_peptide_or_its_receptor_for_migraine_prevention_ L2 - https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-018-0955-y DB - PRIME DP - Unbound Medicine ER -